At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase Ib Study of Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
In Brief
A Phase 1 clinical trial evaluating Pembrolizumab for Esophageal Squamous Cell Carcinoma. Completed, enrolled 20 participants across 1 site.
Detailed Summary
This study will evaluate the safety and feasibility of preoperative immune checkpoint therapy with concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. And this study will provide valuable information for further clinical trials of preoperative pembrolizumab and other immune checkpoint therapy in esophageal cancer treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEsophageal Squamous Cell Carcinoma
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedJan 2019
Enrollment StartJan 2019
Primary CompletionMar 2020
Study CompletionJun 2020
TodayJul 2026
First PostedJan 3, 2019
Enrollment StartJan 21, 2019
Primary CompletionMar 17, 2020
Study CompletionJun 17, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 7.5 years ago
Interventions
Pembrolizumabdrug
Arm1：Pre-operative Pembrolizumab+chemoradiotherapy